pablo schffner

Tupcal pivoted from AI weight-loss tracker via WhatsApp to white-label Ozempic subscription model, went to US to validate, now doing tens of millions ARR with 5 people. Exemplifies catching the GLP-1 wave at right time.

OpenAI tied to Azure; Anthropic's multi-cloud flexibility (AWS, GCP, Azure) lets them optimize cost/performance. Microsoft also secured Pentagon deal after Anthropic refused.

Google is a key Anthropic investor ($2B) enabling multi-cloud strategy, but also launching Fitbit Air ($99, no subscription) targeting mass Android users with Google Health integration to capture health data at scale. Different target than Whoop's elite athletes.

Spanish alcohol producer Codorníu (Foro Founders portfolio) holding excess high-proof inventory; GLP-1 adoption reduces alcohol cravings, making it bad time to sell. Alcohol giants stocked up post-COVID, now facing demand destruction.

GLP-1 agonists (Ozempic, Wegovy, Mounjaro) used by 25% of Americans heading to 35%, $250/month recurring for life with documented 15-20% weight loss and metabolic benefits. Disrupting alcohol, junk food, creating adjacent markets (telemedicine, protein foods, smaller portions). Portfolio company Tupcal pivoted to white-label GLP-1 subscription doing tens of millions ARR with 5 people.

Eli Lilly's tirzepatide (Mounjaro/Zepbound) is the other major GLP-1/GIP dual agonist driving the metabolic drug wave, with same recurring revenue dynamics and market disruption as Novo Nordisk's semaglutide.

Anthropic captures 40% of enterprise AI spend vs OpenAI's 27% by focusing exclusively on enterprise-first APIs and coding (Claude Code), leveraging constitutional AI safety branding to win trust, and using multi-cloud (Amazon Trainium chips) to achieve 70% margins. Revenue grew from $87M to $45B ARR in 2 years.

Amazon invested $3B in Anthropic and provides cheaper Trainium chips vs Nvidia, allowing Anthropic multi-cloud flexibility and 70% margins. Anthropic can choose best price/performance across AWS, GCP, Azure.